Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 12/20 | 0.55 |
| ▸ | RHEB | Q15382 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908754 | 0.90 | S1PR2 (0.67) | S1PR2RHEBPRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23908873 | 0.90 | S1PR2 (0.68) | S1PR2RHEBPRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23908798 | 0.87 | S1PR2 (0.66) | S1PR2PRKAG1PRKAA2PRKAA1PRKAB1 | |
| SCHEMBL23908727 | 0.85 | S1PR2 (0.69) | S1PR2PRKAG1PRKAA2PRKAA1PRKAB1 | |
| SCHEMBL23908751 | 0.84 | S1PR2 (0.67) | S1PR2PRKAG1PRKAA2PRKAA1PRKAB1 | |
| SCHEMBL23915330 | 0.82 | S1PR2 (0.56) | S1PR2RHEBMAPT | |
| SCHEMBL23915346 | 0.81 | S1PR2 (0.55) | S1PR2RHEBCNR2 | |
| SCHEMBL23914689 | 0.79 | S1PR2 (0.60) | S1PR2PTGDR2AKR1B1MAPT | |
| SCHEMBL23915323 | 0.79 | S1PR2 (0.54) | S1PR2AKR1B1MAPT | |
| SCHEMBL23914679 | 0.79 | S1PR2 (0.56) | S1PR2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |